Rumi Minami

Fukuoka, Japan

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 29 publications

Frailty and associated clinical factors among Japanese people with HIV: A multicentre cross-sectional study using the revised Japanese Cardiovascular Health Study criteria.

Frailty and associated clinical factors among Japanese people with HIV: A multicentre cross-sectional study using the revised Japanese Cardiovascular Health Study criteria.

Journal: HIV medicine
Published: May 14, 2026

A Fatal Case of AIDS Complicated by Kaposi's Sarcoma-associated Inflammatory Cytokine Syndrome (KICS).

A Fatal Case of AIDS Complicated by Kaposi's Sarcoma-associated Inflammatory Cytokine Syndrome (KICS).

Journal: Internal medicine (Tokyo, Japan)
Published: May 06, 2026

Position-5-Driven Reorientation of an Immunodominant HLA-A*24:02 SARS-CoV-2 Epitope Drives Universal T-cell Escape.

Position-5-Driven Reorientation of an Immunodominant HLA-A*24:02 SARS-CoV-2 Epitope Drives Universal T-cell Escape.

Journal: JCI insight
Published: March 17, 2026

Position-5-driven reorientation of an immunodominant HLA-A*24:02 SARS-CoV-2 epitope drives universal T cell escape.

Position-5-driven reorientation of an immunodominant HLA-A*24:02 SARS-CoV-2 epitope drives universal T cell escape.

Journal: JCI insight
Published: November 13, 2025

Twenty-four month effectiveness and safety of bictegravir/emtricitabine/tenofovir alafenamide in people with HIV: Real-world data from the BICSTaR Japan cohort.

Twenty-four month effectiveness and safety of bictegravir/emtricitabine/tenofovir alafenamide in people with HIV: Real-world data from the BICSTaR Japan cohort.

Journal: Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy
Published: October 06, 2025

SARS-CoV-2 Spike-specific T Cell Responses Following COVID-19 Vaccination in Japanese People Living with HIV.

SARS-CoV-2 Spike-specific T Cell Responses Following COVID-19 Vaccination in Japanese People Living with HIV.

Journal: Japanese journal of infectious diseases
Published: June 29, 2025

Evaluation of cabotegravir plus rilpivirine in routine clinical settings in Japan: A multicentre study of efficacy, safety and biomarker dynamics.

Evaluation of cabotegravir plus rilpivirine in routine clinical settings in Japan: A multicentre study of efficacy, safety and biomarker dynamics.

Journal: HIV medicine
Published: May 04, 2025

Molecular basis of potent antiviral HLA-C-restricted CD8+ T cell response to an immunodominant SARS-CoV-2 nucleocapsid epitope.

Molecular basis of potent antiviral HLA-C-restricted CD8+ T cell response to an immunodominant SARS-CoV-2 nucleocapsid epitope.

Journal: Nature communications
Published: January 08, 2025

Bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in treatment-naïve and treatment-experienced people with HIV: 12-month virologic effectiveness and safety outcomes in the BICSTaR Japan cohort.

Bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in treatment-naïve and treatment-experienced people with HIV: 12-month virologic effectiveness and safety outcomes in the BICSTaR Japan cohort.

Journal: PloS one
Published: July 08, 2024

Non-acquired immunodeficiency syndrome defining malignancies in people living with haemophilia and human immunodeficiency virus after direct-acting antiviral era.

Non-acquired immunodeficiency syndrome defining malignancies in people living with haemophilia and human immunodeficiency virus after direct-acting antiviral era.

Journal: Global health & medicine
Published: June 08, 2024

Induction of IGHV3-53 public antibodies with broadly neutralising activity against SARS-CoV-2 including Omicron subvariants in a Delta breakthrough infection case.

Induction of IGHV3-53 public antibodies with broadly neutralising activity against SARS-CoV-2 including Omicron subvariants in a Delta breakthrough infection case.

Journal: EBioMedicine
Published: February 13, 2024

Factors Associated with Neutralizing Antibody Responses following 2-Dose and 3rd Booster Monovalent COVID-19 Vaccination in Japanese People Living with HIV.

Factors Associated with Neutralizing Antibody Responses following 2-Dose and 3rd Booster Monovalent COVID-19 Vaccination in Japanese People Living with HIV.

Journal: Viruses
Published: February 08, 2024
Showing 1-12 of 29

Last Updated: 09/26/2026